Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study-Reference-Cited by-同舟云学术

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study

Published:2010-06-29 Issue:9 Volume:25 Page:2846-2850
ISSN:0931-0509
Container-title:Nephrology Dialysis Transplantation
language:en
Short-container-title:Nephrology Dialysis Transplantation

Author:

Locatelli F.,Aljama P.,Canaud B.,Covic A.,De Francisco A.,Macdougall I. C.,Wiecek A.,Vanholder R.,

Publisher

Oxford University Press (OUP)

Subject

Transplantation,Nephrology

Link

http://academic.oup.com/ndt/article-pdf/25/9/2846/5471649/gfq336.pdf

Reference18 articles.

1. The burden of kidney disease: Improving global outcomes

2. European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP)

3. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target

4. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Continuous Erythropoietin Receptor Activator for the Treatment of Chronic Dialysis Patients with Renal Anemia in Daily Clinical Practice in Poland: A Non-Interventional, Multi-Center, Pragmatic NAVIGO Trial;Nephron;2023-09-14

2. The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease;Kidney International;2023-06

3. Peritoneal Dialysis Care in Mainland China: Nationwide Survey;JMIR Public Health and Surveillance;2023-03-14

4. Anemia biomarkers and mortality in hemodialysis patients with or without diabetes: A 10-year follow-up study;PLOS ONE;2023-01-31

5. Resistance to Erythropoiesis Stimulating Agent (ESA) Treatment;Handbook of Dialysis Therapy;2023